专利号:US-10443047-B2 优先权日:2014-05-01 标题 :Increasing cellular lipid production by increasing the activity of diacylglycerol acyltransferase and decreasing the activity of triacylglycerol lipase 发明人:TSAKRAKLIDES VASILIKI; BREVNOVA ELENA E 权利人:NOVOGY INC 摘要:Disclosed are methods and compositions for increasing the triacylglycerol content of a cell by up-regulating diacylglycerol acyltransferase and down-regulating triacylglycerol lipase. In some embodiments, a DGA1 protein is expressed and a native TGL3 gene is knocked out, thereby increasing the synthesis of triacylglycerol and decreasing its consumption, respectively.
专利号:US-2023364251-A1 优先权日:2020-08-06 标 题:Methods for the synthesis of protein-drug conjugates 发明人:BORCHARDT ALLEN; HUGHES ROBERT MICHAEL 权利人:CIDARA THERAPEUTICS INC 摘要:The present invention relates to intermediates and methods for synthesizing protein-drug conjugates that can be used for the treatment of diseases and related conditions.
专利号:US-10472663-B2 优先权日:2015-01-21 标 题:Procedure for the rapid determination of bacterial susceptibility to antibiotics that inhibit protein synthesis 发明人:FERNÃ?NDEZ GARCÃ?A JOSÉ LUIS; GOSÃ?LVEZ BERENGUER JAIME; BOU ARÉVALO GERMÃ?N; TAMAYO NOVAS MARIA; SANTISO BRANDARIZ REBECA; OTERO FARIÑA FÃ?TIMA MARÃ?A 权利人:ABM TECH LLC 摘要:The present invention relates to a method for the rapid evaluation of bacterial susceptibility or non-susceptibility of bacteria to antibiotics that inhibit protein synthesis. The rationale is to identify bacterial responses that depend or are influenced by protein synthesis. If this response is prevented or reduced by the antibiotic that inhibits the protein synthesis, the bacteria are susceptible to this antibiotic. Otherwise, if the response keeps similar despite the incubation with the antibiotic, the bacteria are not susceptible or resistant to this antibiotic. These responses could be determined at the DNA lev-el, cell wall level, morphological level or any other experimental approach, including metabolic, bio-chemical, physiological or genetic processes.
专利号:US-2024207302-A1 优先权日:2021-04-01 标 题 :Antiviral compounds, methods for the manufacturing of compounds, antiviral pharmaceutical composition, use of the compounds and method for the oral treatment of coronavirus infection and related diseases thereof 发明人:CALIXTO JOãO BATISTA; RABI NALLAR JAIME ALBERTO; LOPES E SOUZA THIAGO MORENO 权利人:CALIXTO JOAO BATISTA; RABI NALLAR JAIME ALBERTO; LOPES E SOUZA THIAGO MORENO 摘要:The present invention relates to antiviral compounds selected from cytokinins, their nucleosides and nucleotide analogs, and their prodrugs as inhibitors of viral RNA synthesis, or their salts, solvates, derivatives, or even combinations of aforementioned compounds, for prophylactic treatment, curative (therapeutic) or mitigative coronavirus infection, represented by human and veterinary coronavirus, SARS-COV-2 and MHIV, and for the treatment of individuals potentially exposed to COVID-19. The present invention also comprises the methods for the manufacturing of such compounds, the antiviral pharmaceutical composition containing the compounds of the invention, as well as the use of the compounds, combinations of compounds, and method for the prophylactic, curative (therapeutic) or mitigative treatment of coronavirus infection, represented by coronavirus, in especial SARS-COV-2 and of patients with COVID-19, individual infected with SARS-COV-2 or potentially exposed to this virus. The antiviral activity of the compounds of this invention against SARS-COV-2 was greatly enhanced by inhibiting the 3′-5′-exonuclease. Synergistic results of the compounds according to the present invention were obtained from the combination with repurposed drugs.
专利号:TW-202220698-A 优先权日:2020-08-06 标题:Methods for the synthesis of protein-drug conjugates
专利号:EP-4192512-A1 优先权日:2020-08-06 标题 :Methods for the synthesis of protein-drug conjugates
1: Jadhavar PS, Vaja MD, Dhameliya TM, Chakraborti AK. Oxazolidinones as Anti-tubercular Agents: Discovery, Development and Future Perspectives. Curr Med Chem. 2015;22(38):4379-97. doi: 10.4155/fmc.15.128. Epub 2015 Oct 27. doi: 10.1128/AAC.01691-15. doi: 10.1126/scitranslmed.3009500. doi: 10.1183/09031936.00162314. Epub 2014 Nov 27. Review. doi: 10.1128/AAC.00137-14. Epub 2014 May 12. 7: Werngren J, Wijkander M, Perskvist N, Balasubramanian V, Sambandamurthy VK, Rodrigues C, Hoffner S. In vitro activity of AZD5847 against geographically diverse clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014 Jul;58(7):4222-3. doi: 10.1128/AAC.02718-14. Epub 2014 Apr 28. 8: Zhang M, Sala C, Dhar N, Vocat A, Sambandamurthy VK, Sharma S, Marriner G, Balasubramanian V, Cole ST. In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014 Jun;58(6):3217-23. doi: 10.1128/AAC.02410-14. Epub 2014 Mar 24.
合成参考文献
参考文献:10.1007/s10156-004-0307-5 摘要:Gemmell CG. Glycopeptide resistance in Staphylococcus aureus: is it a real threat J Infect Chemother. 2004 Apr;10(2):69–75. doi: 10.1007/s10156-004-0307-5. 参考文献:10.1128/aac.46.8.2662-2664.2002 摘要:Anderegg TR, Biedenbach DJ, Jones RN. In Vitro Evaluation of AZD2563, a Novel Oxazolidinone, against 603 Recent Staphylococcal Isolates. Antimicrob Agents Chemother. 2002 Aug;46(8):2662–4. doi: 10.1128/aac.46.8.2662-2664.2002. 摘要:Johnson AP. AZD-2563 AstraZeneca. Curr Opin Investig Drugs. 2002 Jun;3(6):848–52. 参考文献:10.1016/j.ijantimicag.2003.05.007 摘要:Anderegg TR, Jones RN. Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone. Int J Antimicrob Agents. 2004 Jan;23(1):6–10. doi: 10.1016/j.ijantimicag.2003.05.007.